Podcasts about Eli Lilly

Beleggers van farmaceut Novo Nordisk zijn afvallig. Het aandeel wordt gedumpt, want de directie komt met misselijkmakend nieuws. Er is voor de tweede keer dit jaar een winstwaarschuwing en als toetje komt daar nog een omzetwaarschuwing bovenop.De verkoop van de afvalprikken van Novo Nordisk vallen tegen. Concurrent Eli Lilly doet het beter. Alleen profiteert het aandeel van de concurrent niet van de neergang van Novo Nordisk. Sterker nog: die gaat ook hard onderuit. Beleggers denken namelijk dat de hele sector overdreven is.Daar hebben we het deze aflevering over. Is de markt voor afvalmedicatie niet gewoon een hype?Hoor je ook over heel veel ander nieuws, want het was een drukke beursdag. Philips bijvoorbeeld, dat hield een zegetocht op de Amsterdamse beurs. Eens géén winstwaarschuwing voor Philips, maar juist een opwaardering voor de winst. Een bedankje daarvoor kan naar het Witte Huis.Waar dan geen muziek in zit, is Spotify. De streamer stelt teleur en dat is heel lang geleden. Er komen meer abonnees bij, maar Spotify maakt onverwachts verlies.Verder in deze aflevering: De Britten hebben een betere deal de EU. Keir Starmer blijkt goede dealmaker Alfen vindt een nieuwe ceo Jerome Powell kan opgelucht ademhalen: Fed-vergaderingen hoeven niet openbaar ECB-werknemers happen juist naar adem. Lagarde zou werksfeer verpesten Kwartaalcijfers van Basic-Fit blijken niet echt fit See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The European Medicines Agency's CHMP did not recommend approving Elevidys for ambulatory patients with Duchenne muscular dystrophy, dealing a blow to Sarepta. FDA is rumored to request new data for Elevidys, leading to uncertainty as FDA considers a new study for the drug. In other news, Eli Lilly commits $856 million to Gate Bioscience for a new class of medicines, while Rocket trims headcount and pipeline focus. Roche also drops an early obesity asset as layoffs continue in the biopharma industry, with companies like Adicet optimizing their pipelines. Novartis makes a billion-dollar drug discovery deal with Matchpoint, and the FDA opens a pilot run of the commissioner voucher program.Stay tuned for more updates on the latest developments in the pharmaceutical and biotech world.

@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technical breakout," and Autodesk's (ADSK) path to reclaim its 52-week high. Rick Ducat gives investors insight into the key levels to watch in the charts.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

Ever wonder how to protect sensitive data when you don't have an IT department? In this revealing conversation, two pharmaceutical industry veterans who recently launched their own consulting businesses share the cybersecurity challenges they never anticipated after leaving corporate America.Katie Hewitt, founder of BioVenture Advisors, and Laura Viaches, president of Endeavor Pharma Solutions, spent over 20 years each at Eli Lilly before venturing out on their own. Their transition from having robust corporate security infrastructure to becoming their own CISOs overnight offers powerful lessons for entrepreneurs handling confidential information. From Katie's experience juggling client demands before even setting up a domain name to Laura's methodical "stealth mode" approach to building secure systems, their contrasting journeys highlight different paths to the same goal: protecting client trust.The conversation reveals startling gaps in the healthcare consulting ecosystem, where clients with valuable intellectual property rarely audit the security practices of their advisors. "I'm more surprised that's not a question they're asking," notes Katie, highlighting how even sophisticated biotech companies often overlook security verification until regulatory requirements or funding rounds force the issue.Cybersecurity experts Aaron, Todd, and Cody offer practical advice for entrepreneurs navigating these challenges without enterprise budgets. Their recommendations focus on process-first approaches – identifying critical assets, working in client environments whenever possible, and implementing basic controls like multi-factor authentication before investing in complex solutions. The group explores how AI tools create new security considerations, particularly around meeting documentation and data retention.Whether you're launching a new venture or helping clients through their growth journey, this discussion delivers actionable insights about balancing security with entrepreneurial agility. The most valuable takeaway? "If you're a small business entrepreneur, you are the CIO and you are the CISO," Katie reminds us – taking this responsibility seriously from day one can transform security from a burden into a competitive advantage.

A surge in private market investment has Fools wondering: is it time to bet bigger on biotech? Tim Beyers and Karl Thiel discuss: - The rise in biotech funding from VCs and wealthy individuals. - The key attributes of an investable biotech. - Which is the better biotech: Viking Therapeutics or Eli Lilly? Companies discussed: VKTX, LLY, MRK Host: Tim Beyers and Karl Thiel Producer: Anand Chokkavelu Engineer: Dan Boyd, Natasha Hall Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Want to double your ticket average without being pushy? Get access to real-time sales training, scripts, and role-play coaching inside the Blue Collar Closer community — join today before the next live Q&A drops: https://wastenoday.pro/BCC Join the Waste No Day! Facebook group: https://wastenoday.pro/FBgroup   Laura Kelly is the co-founder of Clover and a leader in business psychology and optimal human performance. She's consulted one-on-one with billion-dollar businesses, worked with global brands like Dell and Eli Lilly, and helped hundreds of contractors achieve consistent growth through Clover's contractor education programs.   In this episode, we talked about personal development, leadership mindset, psychological safety, courageous action, limiting beliefs...

Frank Holland and the Investment Committee debate the future of the rally as next week brings key economic data and quarterly earnings from nearly 20% of the S&P.  Plus Kevin Simpson making some major portfolio moves, he shares them all with the Committee. And later, we hit the latest Calls of the Day on Eli Lilly and Materion. Investment Committee Disclosures

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über einen Mega-Deal von Lucid, Billionen-Träume bei Netflix und den Absturz von Jungheinrich. Außerdem geht es um Quantumscape, Bigbear.AI, Aeva Technologies, D-Wave, Archer Aviation, Intuitive Machines, Rocket Lab, AST Spacemobile, Netflix, Disney, ComCast, Warner Brothers Discovery, Uber Technology, Interactive Brokers, TSMC, ASML, PepsiCo, Taiwan Semiconductor, Novartis, Richemont, ABB, Siemens, Salzgitter, Burberry, American Express, Tema Neuroscience and Mental Health ETF (WKN: A408EL), Vertex Pharmaceutical, Eisai, Biogen, Eli Lilly, DexCom, Siemens Healthineers, Johnson&Johnson, Pfizer, Lindbeck, GSK, Atai Life Science, Mind Medicine, iShares Core MSCI World (A0RPWH), Xtrackers MSCI World USD (A1XB5U), Vanguard FTSE All-World USD (A2PKXG), Xtrackers AI & Big Data (A2N6LC), Amundi MSCI World USD (ETF146), Amundi Core Stoxx Europe 600 (LYX0Q0), iShares MSCI ACWI (A1JMDF), Xtrackers II EUR Overnight (DBX0AN), WisdomTree Europe Defence ETF (A40Y9K), HanETF Future of Defence ETF (A3EB9T). Habt Ihr suizidale Gedanken, oder habt Ihr diese bei einem Angehörigen/Bekannten festgestellt? Hilfe bietet die Telefonseelsorge: Anonyme Beratung erhält man rund um die Uhr unter den kostenlosen Nummern 0800 / 111 0 111 und 0800 / 111 0 222. Auch eine Beratung über das Internet ist möglich unter http://www.telefonseelsorge.de. Eine Liste mit bundesweiten Hilfsstellen findet sich auf der Seite der Deutschen Gesellschaft für Suizidprävention. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This podcast episode is designed to offer listeners a discussion about the FDA's evolving stance on animal testing and exploring thoughts on its potential phase-out for monoclonal antibody (mAb) therapies. Hosted by Zac Lloyd and featuring expert insights from Dr. Whitney Helms, Executive Director of Nonclinical Development, Large Molecule Discovery at Eli Lilly and Company, and Dr. Diann Blanset, consultant at Akkeri, Inc., this roundtable-style discussion unpacks the scientific, ethical, and regulatory implications of this paradigm shift. Whether you're deep in the biologics pipeline or navigating the changing CRO landscape, this episode offers valuable perspectives on what the future may hold—and how to prepare for it.

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Julie Vose, University of Nebraska Medical Center, Omaha, US, discussing unmet needs in the treatment of MCL. Vose provides an overview of the current treatment landscape for patients with MCL, including Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies. Vose also discusses mechanisms of resistance to BTKi and the impact on patient outcomes. This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

Up to 3,500 FDA staffers received their final walking papers Monday after the U.S. Supreme Court found last week that the government is “likely to succeed” in arguing that its overhaul of HHS is “lawful.” Meanwhile, FDA Commissioner Marty Makary floated policy changes for the agency, including a proposal to lower prescription drug user fees for the next iteration of the program, and one to offer speedier reviews to companies willing to lower the cost of their drugs.  Last week, the regulator opened its cache of complete response letters (CRLs), offering transparency into the rationale behind more than 200 recent rejections for ultimately approved therapies, including those for Eli Lilly's Alzheimer's drug Kisunla and Sarepta's Duchenne muscular dystrophy (DMD) treatment Vyondys 53. The FDA did not, however, release the CRLs for two new rejections: those of therapies from Ultragenyx and Capricor Therapeutics in Sanfilippo syndrome type A and cardiomyopathy associated with DMD, respectively. It was an especially rough week for Ultragenyx, which also, along with partner Mereo BioPharma, released seemingly negative Phase II/III data for their osteogenesis imperfecta therapy.  On a more positive note, two bustling therapeutic spaces continue to see positive data. In obesity, Hengrui Pharma's Kailera Therapeutics–partnered dual GLP-1/GIP receptor agonist elicited 17.7% average weight loss in a pivotal Chinese trial. And the psychedelic therapeutics space is again generating excitement with two recent positive readouts in treatment-resistant depression. BioSpace took a deep dive into the market reaction to these readouts for Compass Pathways and Beckley Psytech and atai Life Sciences, and what exactly investors are looking for in a successful psychedelic therapy.  Finally, we examine the progress of AI biotech unicorns and kick off our series on women in biopharma with profiles on Mayo Venture Partner Audrey Greenberg and the all-female CEO/R&D tandem at Acadia Pharmaceuticals.  

In this episode, we dive deep into the biggest stories shaping the markets right now. Intel has officially fallen out of the top 10 semiconductor companies — is it too late for them to catch up, and which 3 chipmakers should investors focus on instead? We also break down how stock options can be used as a powerful wealth-building tool when used the right way.With Nvidia flirting with a $4 trillion valuation after an explosive 870% AI-led rally, we discuss whether it's headed for a meltdown or another breakout — and which overlooked metric might signal what's next. Bitcoin also hit a new all-time high heading into Crypto Week, and we break down what this means for the broader crypto market.Next, we analyze who the real winners and losers in Big Tech have been since Trump took office, and what it means for investors moving forward. With U.S. equity fund inflows collapsing from $31.6 billion to just $2.1 billion, we ask: are you buying the dip or parking cash on the sidelines? Lastly, we look at Eli Lilly and whether its new Zepbound pill could drive a potential 40% surge in the stock over the next year.EYLU 24 Hour 50% off Sale (Code: Marketmondays) https://eyluniversity.comInvest Fest Ticket Link: https://investfest.com#Investing #StockMarket #Crypto #Bitcoin #Nvidia #Intel #EliLilly #Zepbound #TechStocks #InvestFest #EarnYourLeisure #MarketMondays #FinancialFreedom #OptionsTradingOur Sponsors:* Check out PNC Bank: https://www.pnc.comSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Jim has led ESG efforts at Eli Lilly since September 2020. In this capacity, he oversees implementation of Lilly ESG strategy, has responsibility for coordinating ESG-related communications, and organizing and leading ESG stakeholder interactions.  In a significant advancement of Lilly's approach, Jim led the development of Lilly's ESG portal, a comprehensive source for ESG strategy, goals and results.  Jim also chairs the ESG Governance Committee at Lilly, which is a central body for development and execution of ESG priorities and communication to the Executive Committee and Board of Directors. Prior to his current role, Jim spent two years as a loaned executive to Elanco Animal Health, which was spun out of Lilly in an IPO in 2018.  Jim served as the Vice President of Investor Relations at Elanco.  He was responsible for leading all interactions with Sell-Side Analysts and Buy-Side Investors, including preparation of Earnings materials, participation in Investor Conferences, Non Deal Roadshows and investor visits to Elanco Headquarters.  He conducted investor outreach and targeting to build understanding of the Elanco investment thesis.  He worked closely with External Communications to provide consistent external dialogue and to prepare Elanco Senior Executives on key topics and messaging on relevant issues.  In 2020, Jim was ranked the number one IR leader for mid-cap pharmaceuticals by Institutional Investor. Prior to the role at Elanco, Jim spent 18 years at Lilly, holding numerous positions of increasing responsibility, including an assignment in Corporate Business Development, managing Lilly's Venture Capital portfolio.  Jim has also served as the Chief Financial Officer of Lilly Canada, Senior Director of Finance for Lilly Research Laboratories, Manager of Investor Relations, Manager of Treasury Planning and Strategy, Senior Human Resources Representative and Senior Financial Analyst. Prior to joining Lilly, Mr. Greffet was a Consulting Manager for KPMG Consulting in Indianapolis, Indiana and St. Louis, Missouri. Jim Joins Sustainable Nation to Discuss: Eli Lilly's Approach to ESG Lilly's 30 by 30 initiative to improve healthcare for 30 million people by 2030 Progress toward goals and targets without the use of carbon offsets Advice and recommendations for sustainability professionals Jim's Final Five Questions Responses: What is one piece of advice you would give other sustainability professionals that might help them in their careers?  Two words. Be pragmatic. This was a theme that came up in our conversation. There's the lunatic fringe on everything, and certainly in this space, on both ends of the spectrum. Tie your sustainability work to the purpose of your organization, be pragmatic, think in common sense terms, and you'll make a whole lot more progress.  What are you most excited about right now in the world of sustainability?  In the short four and a half years, this world has changed a lot. I think when I first came into it, it was sporadic, voluntary reporting by organizations, maybe a little bit of ‘accentuate the positive.' It evolved into more rigorous and disciplined financial reporting. Over the last 18 months or so, I think we've seen the heavy hand of regulation start to come about, especially in Europe, which creates a lot more overhead. I think all of us would rather deploy our energy and resources to doing things than reporting about them. So to the exciting part, I now think we're starting to see a little bit more sensibility prevail in some of these regulations, maybe lifting the heavy hand of regulation a little bit so that we can have consistent, rigorous, well constructed reporting that's doable and doesn't take us away from the mission that we have in front of us. I'm optimistic and excited that we're going to land in a spot that's doing the right thing for the right reasons, consuming the right amount of energy.  What is one book you'd recommend sustainability professionals read?  George Seraphim, Purpose + Profit. He's a Harvard Business professor and he taught, you can see from the name of that book, Purpose plus Profit. It takes this pragmatic view of why sustainability can help you run your business better, not just be a fringe idea that's detached from what the business is supposed to do.  What are some of your favorite resources or tools that really help you in your work?  I'll give one shout out. Brian Matt with the New York Stock Exchange puts out an email each Friday called the ESG Top five. It's the top five sustainability topics of the week. He commits that it's a two minute read. If you get interested, it's going to be more than a two minute read, but you can certainly get the headlines in two minutes. There's certain emails that I can't delete fast enough. That's one that I open every time and I always learn something out of it.  Where can our listeners go to learn more about you and the work being done at Eli Lilly?  Sustainability.lilly.com. My performance is tied to website hits, so all your listeners, please open it up first thing when you get in the morning and hit refresh many times during the day. You'll do me a solid on my performance. Then LinkedIn, I have a LinkedIn page as well that captures some of the stuff we're doing here.  

As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.Contextualizing the appetite for GLP-1s (0:46)Build, buy, acquire: How Novo Nordisk and Eli Lilly are meeting demand (04:05)The implications of Novo Nordisk's $16.5 billion Catalent acquisition (05:53)How to decide whether to acquire or outsource (07:23)Where in the world is GLP-1 manufacturing going next? (10:36)DTC, telehealth, and the future of GLP-1 channel strategy (13:16)How AI is driving pharma innovation at Novo Nordisk, Eli Lilly, Johnson & Johnson, and Merck (17:13)

Ever worked somewhere that claimed "we're a family" but treated you like anything but? Stephen Bump has seen both sides—and he's building something different with Persperity.In this conversation with Cam and Otis, Stephen shares his journey from Air Force leadership to founding a consultancy that's deliberately challenging the "always-on" culture of modern business. "They actually treated people really well and understood that people had a life outside of work," he reflects about a former employer that got it right.From battling his own "shiny object syndrome" to making tough calls about which opportunities to pursue, Stephen offers a refreshingly honest look at the early stages of building a purpose-driven business. Plus, Otis shares a laugh-out-loud story about military decision matrices that anyone who's ever had their carefully-crafted presentation ignored by the boss will relate to.Whether you're scaling a business, leading a team, or just trying to find work that respects your whole life, Stephen's practical approach to building a company that values both results and people will leave you with actionable insights.More About Stephen:Strategic leader with deep expertise in life sciences, defense, and aerospace. At Persperity, I lead multi-million dollar initiatives for Fortune 500 clients, enabling them to scale within regulated industries. My career spans high-stakes program management with the U.S. Air Force, impactful continuous improvement projects at Eli Lilly, and Lean Six Sigma transformations. I started Persperity for two reasons: to help life sciences companies break through manufacturing and regulatory roadblocks so they can scale fast and meet demand, and to give employees the flexibility they crave without losing sight of meaningful, purpose-driven work. #10xYourTeam #LeadWithPurpose #PeopleOverProcess #AntiAlwaysOn #WorkLifeRespect #PurposeDrivenLeadership #BuildBetterCulture #FromMilitaryToMission #StartUpWithSoul #RealLeadershipMatters #NoMoreFakeFamilyChapter Times and Titles:The "We're a Family" Business Trap [00:00 - 12:00]Introduction to Stephen BumpThe problem with companies claiming to be "family"What good employers do differentlyLife Outside of Work Matters [12:01 - 17:00Building flexibility into early-stage businessesHow different life phases change what employees valueStephen's approach at PersperityFighting Shiny Object Syndrome [17:01 - 25:00]"Just because there's an opportunity doesn't mean you should go after it."Defining your business focusStrategic decisions in life sciences manufacturingWhen Gut Feeling Trumps Analysis [25:01 - 30:00]Otis's military decision matrix storyThe value of the process, even when the outcome is predeterminedFinding a balance between analysis and intuitionWorking On vs. In the Business [30:01 - 40:00]Stephen's honest struggle with stepping back"For me, working on the business means doing billable work."Building fences to prevent founder burnoutConsulting Relationships That Work [40:01 - End]The challenge of clients who don't follow adviceBuilding trust through expertiseFinal thoughts on creating meaningful workStephen BumpWebsite: https://persperity.net/

In this explosive and highly anticipated episode, Dr. Roger McFillin hosts Dr. Ragy Girgis, a Columbia University Professor of Psychiatry and researcher, for a no-holds-barred confrontation that exposes the shocking divisions tearing apart the mental health field. What begins as a conversation about mass violence research rapidly explodes into a devastating examination of psychiatric medicine's crumbling foundations, questionable effectiveness, and devastating potential harms. The two clash in fierce, unrelenting disagreements over fundamental issues including the validity of DSM diagnoses, the debunked "chemical imbalance" theory of depression, dangerous SSRI safety cover-ups and black box warnings, corrupted research quality and pharmaceutical industry manipulation, and the catastrophic crisis of psychiatric drug overprescription poisoning 1 in 4-5 Americans. Dr. Girgis desperately defends traditional academic psychiatry and current treatment approaches, while Dr. McFillin ruthlessly dismantles the entire paradigm, arguing that the current system is systematically creating chronic mental illness rather than healing it. Buckle up for this brutal intellectual warfare.___________________________________________________________________________________________________________________________________________________Throughout the interview, Dr. Girgis repeatedly stated that "the data is clear" while dismissing contradictory evidence that challenges his conclusions. For our listeners' benefit, I have compiled research and documentation that directly disputes several of Dr. Girgis's key claims.Serotonin Hypothesis of Depression1. The serotonin theory of depression: a systematic umbrella review of the evidence (Moncrieff et al.)Conclusions: "This review suggests that the huge research effort based on the serotonin hypothesis has NOT produced convincing evidence of a biochemical basis to depression. This is consistent with research on many other biological markers . We suggest it is time to acknowledge that the serotonin theory of depression is NOT empirically substantiated."2.What has serotonin to do with depression?Conclusions: "Simple biochemical theories that link low levels of serotonin with depressed mood are no longer tenable."3. Is the chemical imbalance an ‘urban legend'? An exploration of the status of the serotonin theory of depression in the scientific literatureViolence & Suicide Associated with SSRI's 1. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers2. Prescription Drugs Associated with Reports of Violence Towards Others3. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family4. Lexapro Approved for Pediatric Use Despite the 6-Fold Increase in Suicide Risk5. McFillin Substack Review on Lexapro approved despite Suicide Risk6. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports7. Antidepressants Increase Suicide Attempts in Youth; No Preventative Effect8. Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk:9.  FDA Warning: Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents10.  Suicide Mortality in the United States, 2001–2021 CDC documentation11. US suicide rate reaches highest point in more than 80 years: See what latest data shows12.  CNN article reporting Eli Lilly Internal Documents"An internal document purportedly from Eli Lilly and Co. made public Monday appears to show that the drug maker had data more than 15 years ago showing that patients on its antidepressant Prozac were far more likely to attempt suicide and show hostility than were patients on other antidepressants and that the company attempted to minimize public awareness of the side effects. The 1988 document indicated that 3.7 percent of patients attempted suicide while on the blockbuster drug, a rate more than 12 times that cited for any of four other commonly used antidepressants.In addition, the paper said that 1.6 percent of patients reported incidents of hostility -- more than double the rate reported by patients on any of four other commonly used antidepressants."Examples of Violence after Prescription in legal system (Sample)January 24, 2020 – Newcastle, South Dublin, Ireland: Deirdre Morley, 44, smothered and killed her two sons Conor, 9, and Darragh, 7, and her three-year-old daughter Carla McGinley in their family home. She had been taking antidepressants since October 2018 and was admitted to St. Patrick's Mental Health Services on July 6, 2019, but was discharged after a short period, but was put on a combination of two antidepressants and a sedativeMay 11, 2018 – Osmington, Western Australia: Peter Miles, 61, shot his 35-year-old daughter and four grandchildren, aged 8 through 13, while they slept in their beds, in a shed that had been converted to a second house on the property. He then turned the gun on his 58-year-old wife in the living room of their house, before placing a call to police alerting them to his crimes. When they arrived, Miles was also found dead from a gunshot wound. Miles had started taking antidepressant medication just weeks before.April 6, 2018 – Wadsworth, Ohio: Gavon Ramsay, 17, strangled his neighbor, 98-year-old Margaret Douglas in her own home. His parents blame his actions on his having been misprescribed Zoloft. After a report by his school principal that the teen was depressed and might harm himself, he “returned to therapy,” and after a recommendation by a psychologist, the family's pediatrician prescribed the antidepressant Zoloft. From January through March leading up to the incident, the dosages were increased. During this time, his mother said she observed her son's behavior change—becoming increasingly irritable and hostile and saying bizarre things.October 21, 2013 – Sparks, Nevada: 12-year-old Jose Reyes opened fire at Sparks Middle School, killing a teacher and wounding two classmates be...

Dan Deming joins today's Big 3 and turns to three stocks that he believes investors should keep on their radar as the market "broadens." He talks about the potential for Broadcom (AVGO) to continue its rally after its tremendous run higher, Eli Lilly's (LLY) role in the "vanity trade," and Uber Technologies (UBER) finding its "niche" as autonomous driving evolves. Rick Ducat gives investors insight into the bearish and bullish indicators he found in the charts.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über den neuen Drohnen-Liebling, einen Bitcoin-Rekord und die Rückkehr des Wasserstoff-Hypes. Außerdem geht es um Volatus Aerospace, WK Kellog, EssilorLuxottica, Meta Platforms, Plug Power, Bloom Energy, Ballard Power, L&G Hydrogen Economy ETF (WKN: A2QMAL), Hershey, Nvidia, Apple, Microsoft, Standard Oil/ExxonMobil, General Electric, NTT, Intel, Texas Instruments, Micron Technology, Eli Lilly, Merck, Air Products, Freeport-McMoran, Keysight, Hess, Williams, EQT, Amundi MDax ETF (WKN: LYX0R1), RWE, National Grid, Rio Tinto, Antofagasta, Infineon, ASML, SAP, Leonardo, Astrazeneca, Merck, Novo Nordisk, Almonty Industries. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

You are in for a special treat as Dee Greer displays her creations of exquisite weavings from Alpaca yarn and amulet bags woven Japanese seed beads. She also enjoys watercolor painting. She learns in order to create. This is bolstered by degrees and certifications in the arts, financial planning, hand weaving, and interior design. Dee has created five businesses in rehab housing, five in Alpaca-related products and services, and a unique hand-weaving loom. Hurricane Helene completely destroyed her condo interior and precious belongings, including a specialty loom. Dee has rebuilt and redesigned her unit, along with helping 60 other residents facing the same challenge. She still makes the time to volunteer with arts programs in her community and to enjoy the rich arts culture with her partner, John. Dee's constant ‘drivers' are “doing good in the world” and “being in relationship with people, young and old… to enjoy life from completely different perspectives.”  Hoping to help find a cure, she has now been accepted into a study sponsored by Eli Lilly to study a new drug for the treatment of Alzheimer's disease. Because I have so many interests and very high energy, I've had to compartmentalize and prioritize. It will come to me what to do next. - Dedrea (Dee) GreerContact Dedrea (Dee) GreerEmail: deeagreer@hotmail.com Former alpaca farmer finds tranquility while weaving | Your Observer  Sponsor Appreciation  Our heartfelt thanks to Women Over 70 sponsor Wells Fargo.  Podcast Collaborator This month's podcast recommendation (Aging-Well Collaboration) is Host Beverly Glazer, who asks: Are you ready to ignite your next chapter? Aging With Purpose and Passion is the weekly podcast inspiring women over 50 to embrace bold life shifts, and unlock their potential, through captivating stories from trailblazing senior women. https://www.agingwithpurposeandpassion.com 

While most of the U.S. was celebrating the 4th of July holiday, President Donald Trump was busy signing the One Big, Beautiful Bill into law. This wide-ranging tax law has a few implications for the biopharma industry, including expanded IRA exemptions for orphan drugs.  Looking ahead to the second half of 2025, BioSpace reviews some of the upcoming catalysts highlighted by Jefferies' “Halftime Show” report,including a highly anticipated Phase III readout for Eli Lilly's oral obesity candidate orforglipron and an eye on rare disease decisions under the “new” FDA.  Speaking of FDA decisions, this week kicked off with a surprise approval—that of KalVista's Pharmaceuticals' Ekterly for hereditary angioedema. The road to approval for Ekterly was not a smooth one, after the FDA delayed its target action date and Endpoints News reported that FDA Commissioner Marty Makary tried to have the application rejected.  More regulatory controversy is afoot as Health Secretary Robert F. Kennedy Jr. is facing yet another lawsuit. A group of medical organizations have sued Kennedy and other health leaders in an attempt to reverse Kennedy's recent decision to remove COVID-19 shots from the routine immunization guidelines for healthy children and healthy pregnant women. In other vaccine news, Kennedy endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are at risk of severe disease—following the recommendation of the CDC vaccine advisory committee he turfed last month.  This seeming reversal of sentiment largely mirrors the Secretary's massive HHS overhaul, which has already seen several of these layoffs reversed. In ClinicaSpace this week, we take a deep dive into the numbers. Also in ClinicaSpace, we feature four therapies hanging tough in a troubled TIGIT space that has seen several companies burn billions of dollars on failed assets. And BrainStorm Cell Therapeutics is back in the news after signaling support for a Citizens' Petition submitted to the FDA requesting the approval of its cell therapy NurOwn, whose Biologics License Application was withdrawn in 2023.  Finally, in BioPharm Executive, we take a deep dive into the burgeoning longevity space and unpack the short-lived marriage between Novo Nordisk and Hims & Hers Health.   

“Action over words.” “Where you can show up, show up.” “It doesn't cost anything to be nice.” “The physical embodiment of love is being present.”   Episode summary | In this episode of the Return on Generosity podcast, host Jabari Whitehead engages with guests Tay Person and Mike Wernert in a heartfelt discussion about the importance of generosity, support, and emotional presence in parenting. They explore the challenges of being sports parents, the lessons of character and generosity they hope to impart to their children, and the value of being present in their kids' lives. The conversation also touches on the complexities of travel sports and the cherished moments that make it all worthwhile.   R.O.G. Takeaway Tips | Your circle reflects who you aspire to be. Creating a loving environment is crucial for growth. Mistakes are part of the learning process. Being present is essential for emotional support. Generosity can make the world a better place. Travel sports can provide valuable life lessons. It's important to support your child's passions. Emotional openness is key in parenting. Intentionality in parenting leads to better outcomes. Cherished moments with family are invaluable.   Chapters |  00:00 Better Us, Better Them 01:59 Lessons from Sports Parenting 08:43 Navigating Academic Pressure and Emotional Support 10:47 The Importance of Preparation and Goal Setting 12:32 The Invisible Work of Being Present 20:05 Emotional Vulnerability in Competitive Environments 26:57 Lessons of Generosity and Character 30:30 The Value of Travel Sports and Family Moments 35:36 Daily Moments of Joy and Connection   Guest Bio | Mike Wernert: Michael J. Wernert is a respected pharmaceutical leader and U.S. Army veteran known for his authentic, fatherly approach to leadership, with a career spanning 20 years at AstraZeneca and Eli Lilly. Michael's experience as a teacher, coach, and military officer has shaped his belief that leadership is about investing in people and celebrating their successes. Armed with an MBA from the University of Delaware, a Master's in Education from West Chester University, and a distinguished military background, he combines strategic expertise with genuine care and support for those around him.   Tay Person: With over 20 years of experience in K-12 education, Tay has spent his professional career dedicated to improving outcomes in public education. As a teacher, board member, consultant, and leader, Tay has taken a consultative approach to drive results and build lasting partnerships that ultimately benefit children. When he's not working he's spending time with his four daughters and wife of twenty-two years.   Guest Resources:  The Power of Vulnerability - Brene Brown: https://www.ted.com/talks/brene_brown_the_power_of_vulnerability?language=en   Bridge Between Resources: 5 Degree Change Course Free N.D.I. Network Diversity Index  Free Generosity Quiz    Credits: Mike Wernert and Tay Person, Host Jabari Whitehead, Bridge Between, Inc.   Coming Next: Please join us next week for From the Vault #1: Harry Potter.

Enjoy this public release of a members-only show from a few years back! If you want more episodes like this (but without the ads) please go to tiegrabber.com/subscribe or patreon.com/tiegrabber for access. Nailah Franklin was a young pharmaceutical sales rep for Eli Lilly. Until September 2007, she was casually dating Reginald Potts, a 32-year-old businessman. […] The post Dateline Unforgettable Rewatch: Smoke & Mirrors appeared first on Tiegrabber.

A slew of ultra-powerful weight loss drugs are in the pipeline—ironic that Westerners need them so much? RFK Jr. wants every American to wear a fitness tracker; New study upends belief that inflammation is inevitable with aging; Rating products for hair growth and restoration; Why electric vehicles may make us carsick.

When he was elected in 2015 at the age of 26, Matt Gentry was Indiana's second-youngest mayor.  A decade later, he's leading Lebanon through a dramatic transformation, headlined by Eli Lilly and Company's $13 billion investment in the LEAP Innovation District. In this episode, he talks about the challenges and opportunities that change brings, leading at a young age and his vision for reshaping Lebanon for generations to come.

Title: From Properties to Brand with Guest: Darryle Bajomo, Associate Director of Sport & Entertainment Marketing at Eli Lilly

In Part 1 we looked at the basics of a study that compared the two newest GLP-1 weight loss drugs against each other - Novo Nordisk's Semaglutide (Wegovy) and Eli Lilly's Tirzepatide (Zepbound) The trial was funded by Eli Lilly and while many of the authors took money from the makers of both drugs, the only authors (some of whom were statisticians) who were employed by and owned stock in a drug company were from Eli Lilly. While that isn't proof of bias, it's certainly a red flag.Today we'll look at the study and its findings. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. A judge has suspended mass layoffs at the Department of Health and Human Services, ruling that the staff cuts are likely unlawful as the agency does not have the authority to make such changes without Congress. In other news, private equity firms have recently acquired Bluebird Bio, a gene therapy biotech company, raising questions about their motivations. Additionally, RFK Jr. is advocating for changes to the vaccine injury compensation program to include COVID-19 vaccines, while the FDA is considering regulatory action on Argenx's Vyvgart Hytrulo due to safety concerns. The article also discusses Gilead's plans for dominance in the HIV market with a new drug, and other updates in the pharmaceutical industry.Private equity firms are increasingly targeting biotech companies, with Bluebird Bio recently being acquired by two firms. The first half of the year saw a surge in M&A activity in the pharmaceutical industry, with big pharmas like Eli Lilly and Novartis making multiple deals. Deals related to Alzheimer's disease also saw a significant increase following the approval of new treatments. Gilead is expanding its presence in the HIV market with a new drug, while GSK is also vying for market dominance. Other notable deals include AbbVie's acquisition of Capstan and Novartis' partnership for cardiovascular disease targets. Overall, the industry is seeing increased activity and interest from private equity firms and big pharma companies.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.

“Look past people's faults and find their needs.” “I knew I couldn't teach a kid until that kid knew I cared about them or until I made a connection with them.” “The grind is worth it.”   Episode summary | In this episode of the Return on Generosity podcast, host Jabari Whitehead engages in a heartfelt conversation with guests Tay Person and Mike Wernert about the themes of fatherhood, personal growth, and the importance of generosity. The discussion explores how their experiences as fathers shape their values, the lessons learned from their own fathers, and the sacrifices they make for their families. They reflect on the challenges of parenting, the need for self-improvement, and the ways they find balance in their lives. The conversation emphasizes the significance of being role models for their children and the impact of generosity in their relationships. R.O.G. Takeaway Tips | Personal growth is a continuous journey for fathers. Fatherhood involves giving love and discipline. Unlearning old parenting patterns is essential. The first moments of parenthood are transformative. Sacrifices are a part of being a father. Finding time for self-care is crucial for parents. Leadership skills are enhanced through fatherhood. Generosity is reflected in how children treat others. Children observe and learn from their parents' actions. Being a good father requires selflessness and high standards.   Chapters |  00:00 Introduction to Generosity and Personal Growth 03:03 Fatherhood Models and Core Values 03:52 Lessons from Fatherhood: Unlearning and Learning 06:03 Navigating Parenthood: Challenges and Sacrifices 08:13 Refilling the Cup: Self-Care for Fathers 21:16 Reflections on Parenting and Leadership 23:36 Growth in Patience and Understanding 26:51 Authenticity in Leadership 29:22 The Importance of Connection 32:24 Generosity Reflected in Children 39:34 Better Us, Better Them   Guest Bio | Mike Wernert: Michael J. Wernert is a respected pharmaceutical leader and U.S. Army veteran known for his authentic, fatherly approach to leadership, with a career spanning 20 years at AstraZeneca and Eli Lilly. Michael's experience as a teacher, coach, and military officer has shaped his belief that leadership is about investing in people and celebrating their successes. Armed with an MBA from the University of Delaware, a Master's in Education from West Chester University, and a distinguished military background, he combines strategic expertise with genuine care and support for those around him.   Tay Person: With over 20 years of experience in K-12 education, Tay has spent his professional career dedicated to improving outcomes in public education. As a teacher, board member, consultant, and leader, Tay has taken a consultative approach to drive results and build lasting partnerships that ultimately benefit children. When he's not working he's spending time with his four daughters and wife of twenty-two years.   Guest Resources:  The Power of Vulnerability - Brene Brown: https://www.ted.com/talks/brene_brown_the_power_of_vulnerability?language=en   Bridge Between Resources: 5 Degree Change Course Free N.D.I. Network Diversity Index  Free Generosity Quiz    Credits: Mike Wernert and Tay Person, Host Jabari Whitehead, Bridge Between, Inc.   Coming Next: Please join us next week for Episode 240, Part 2.

Following the June 23 OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it's defined, and whether it's truly achievable.To watch the OX40 webinar, please click here.Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

Now that the pathetic cash grab known as the Club World Cup is over (thanks for the 11 million dollars Mr. FIFA), it's time to get down to LAFC's favorite tradition: playing Vancouver. Darren, Vince, and Travis reunite to talk about Ange Postecoglou rumors, Bouanga rumors, Giroud rumors, and of course Eli Lilly's effect on the insulin market. THEN, we are joined by Luke Klipp of Pride Republic to tell us all about Pride Night this Sunday and how you can show your support. Esperance is the greatest club in the history of world football and I want that on the record!!!Join our Patreon and help us keep making this show.Merch and more at HappyFootSadFootPod.comYouTube: @happyfootsadfoot Twitter: @HaFoSaFoInstagram: @happyfootsadfootTikTok: @happyfootsadfoot Hosted on Acast. See acast.com/privacy for more information.

Iran og Israel klarer et døgn uden angreb. Nato lander historisk aftale om at landene skal bruge 5 pct. på forsvar og sikkerhed i 2035. Mujtaba Rahman fra Eurasia Group advarer om højredrejning i Europa. Akademikerpension godkender flere våbenaktier. Eli Lilly vil slå Novo og storsatser på fedmepiller. 33-årig venstrefløjskandidat vinder primærvalg og kan blive borgmester i New York. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce Tuesday, where Democrats confronted the health secretary on hot button issues ranging from his recent overhaul over the CDC's Advisory Committee on Immunization Practices (ACIP) committee, Kennedy's recently published—and error-ridden—MAHA report, and his threat to ban government scientists from publishing in certain medical journals.  Meanwhile, at the FDA, the mass exodus of senior leadership continues. On Monday, Jacqueline Corrigan-Curay, acting head of the Center for Drug Evaluation and Research (CDER), announced her retirement as of July. This follows the ouster of Nicole Verdun—the wildly popular director of the FDA's Office of Therapeutic Products—and her deputy, Rachael Anatol. Their involuntary departure sent shock waves through the biopharma industry, as Verdun had been considered a stabilizing force at the rapidly reshaping agency.  Speaking of the revamped ACIP, the new panel will meet for the first time Wednesday and Thursday to discuss COVID-19 vaccine safety, maternal and pediatric RSV vaccines and more, as experts question the experience and anti-vaccine views of some of Kennedy's recently appointed members and others express concern about the potential politicization of the committee.   On the clinical front, Eli Lilly, Novo Nordisk and others presented new data from their next-generation obesity programs at the American Diabetes Association's 85th Scientific Congress. After failing to impress investors—and meet its own high expectations—with CagriSema, Novo sought to reassure investors by touting a safety profile “in line with the GLP1-RA class,” and Eli Lilly reported that bimagrumab, when used alongside Novo's Wegovy, led to additional weight loss while also preserving muscle mass.  Finally, we recap BIO2025, where Jef Akst, Lori Ellis and Heather McKenzie moderated panels on cell and gene therapy, cybersecurity and AI, and accelerating market entry for rare disease treatments. Relevant to the latter discussion, congressional Republicans dropped the Orphan Cures Act from their version of President Donald Trump's “One Big Beautiful Bill Act,” and congresspeople, including Rep. Gus Bilirakis (R-Fla.) at Tuesday's hearing asked Kennedy to commit to supporting the priority review program for rare pediatric diseases, which expired at the end of last year.  

Publicly traded U.K. investment firm and company builder Syncona is restructuring its fund amid ongoing market challenges in the biopharma industry. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how the firm will steer its portfolio toward returns for shareholders, while aiming to build a new fund away from public markets. The analysts then assess Eli Lilly's takeout of cardiovascular base editing company Verve, and what Washington Editor Steve Usdin calls FDA's new “two-track” future for evaluating new therapies for approval — those with clear-cut benefits and those with ambiguous efficacy safety and efficacy profiles — in light of the many departures of senior FDA staff. They also discuss NASDAQ's largest biopharma IPO — by Caris —  in two years, the latest obesity readouts, FDA Commissioner Marty Makary's priority pathway and Usdin's Q&A with new BIO Chair Fritz Bittenbender. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656266#biotech #biopharma #pharma #lifescience #finance #CV #FDA00:01 - Sponsor Message: ICON Biotech02:14 - Syncona Restructures Fund10:08 - Lilly's $1B Verve Takeout21:45 - FDA's 2-Track FutureTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

This week, the team is joined by Richard Maughan, Senior Director and Head of UK Policy and Public Affairs, Pfizer, to explore how the UK is shaping access to medicine today, and what needs to change in the future. From healthy ageing to the economic cost of respiratory infections, they dive into what the UK is getting right, where it's falling short and why access to medicine matters now more than ever. A little more on EMJ GOLD's guest… Richard is Senior Director and Head of UK Policy and Public Affairs at Pfizer. His team works with public policymakers to deliver breakthroughs that change patients' lives, spanning Pfizer's broad medicines and vaccines portfolio, and deep science footprint. He is a member of Pfizer's UK Senior Leadership Team and Europe Policy & Public Affairs Leadership Team. Prior to Pfizer, Richard was Head of UK Government Affairs for Eli Lilly and Company. He has also worked at the Confederation of British Industry (CBI), the UK's leading business lobbying group. He studied Politics at the University of Edinburgh and the University of California Santa Cruz, and grew up in north-east England.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA's Center for Drug Evaluation and Research (CDER) head, Jacqueline Corrigan-Curay, is leaving the agency in July, becoming the latest in a series of FDA leaders to depart. Eli Lilly is facing concerns about gastrointestinal side effects for their weight loss pill, Orfoglipron, despite brushing off these worries. Vertex's cell therapy for diabetes shows promise, but questions remain about its market potential. HHS Secretary Robert F. Kennedy Jr. has restacked the CDC's vaccine advisory committee, claiming conflicts of interest within the previous group, which experts argue may impact the committee's apolitical nature. Prothena has downsized following a failure in an Al amyloidosis trial, and Novavax is adapting to regulatory uncertainty. Overall, the FDA is experiencing significant turnover in leadership, and challenges persist in drug development and regulation.

Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a focus on the good news that eating more fruits and vegetables has been found to promote better sleep, the brain-health benefits of cycling, and why high blood pressure is linked to developing Alzheimers and other forms of dementias. Continuing with the Alzheimer's and dementia, Doug and Dr. Ken share why sitting too long can raise the risk of developing the progressive neurodegenerative diseases, and how too much time in your seat can undo any amount of exercise in which you partake. Next, the conversation shifts to biological aging on a cellular level, Eli Lilly's acquisition of Verve Therapeutics, and the evolved thinking of cholesterol and that “good cholesterol” isn't as good as once thought. Then, a push from RFK Jr. and members of congress to stop drug companies from advertising on radio and television, how to extend years on your life and age healthily (following a healthy diet like the MIND or Mediterranean Diets, regular physical activity, and cognitive and social engagement), a potential blood test that could indicate how long a person may live, and how the usage of marijuana dramatically increases the risk of dying from a heart attack or stroke. Oh, and there's a new COVID-19 variant (AKA razor blade throat) with a very painful sore throat symptom.Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children. To view the video version of this webinar, please click here. Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

Det kan være svært at bevare optimismen, når nogle af verdens stormagter ser ud til at stå på spring ved våbenarsenalet, men på den anden side ser de globale finansmarkeder dog ikke ud til at være gået helt i panik. Millionærklubben vejrer situationen og debatterer, om man som privat investor bør foretage sig noget. I studiet tjekker teknisk analytiker Lars Persson og Nordnets investeringsøkonom, Per Hansen, markedsåbningen, og med på en telefon fra ADA, American Diabetes Association-konferencen i Chicago, leveres sidste nyt om Novo Nordisk og Eli Lilly af Claus Johansen fra Global Health Invest. Sidst i udsendelsen får vi også et brandvarmt perspektiv på de globale oliemarkeder af Arne Lohmann Rasmussen fra Global Risk Management. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

President Trump called for Iran's unconditional surrender and said he wouldn't target the country's leader “for now.” Plus: Verve Therapeutics shares soar after Eli Lilly agrees to acquire the gene-editing company. And shares of SunRun, Enphase Energy and First Solar sink after Senate Republicans back a phase-out of tax credits in Trump's megabill. Danny Lewis hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

US equity futures are pointing to a lower open today. European markets have opened in the negative territory, following mixed trades in Asian markets. Global markets today are digesting Trump's decision to cut short his G7 attendance to return to Washington after warning on Truth Social for people to evacuate Tehran. BOJ left interest rates unchanged as expected. Ishiba and Trump failed to reach agreement at G7. US and Canada are aiming to strike a trade deal within a month.Companies mentioned: Verve Therapeutics, Eli Lilly, T-Mobile, Softbank

Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline peers. She also notes the sell-off in solar stocks like First Solar (FSLR) after the Senate proposed cuts to wind and solar tax credits. Diane later discusses Eli Lilly's (LLY) $1.3 billion bid for Verve Therapeutics (VERV) and Lennar's (LEN) earnings beat.

The CEO of Cava reacts to a weaker than expect retail sales number, giving his outlook for the consumer and inflation. Then Eli Lilly's acquisition spree continues. More on their latest deal and the company's growth strategy. Plus an exclusive look at Citadel CEO Ken Griffin's advice to the firm's incoming intern class. Carl Quintanilla and Sara Eisen have it all on Money Movers.

Ian Bremmer, president of the Eurasia Group, joins "CBS Mornings" to break down a weekend of deep division in the U.S., as millions protested President Trump and his military parade, and deadly new strikes between Iran and Israel raised fears of a wider regional war in the Middle East. The jury in Karen Read's retrial began deliberations Friday afternoon and will continue Monday. Read is facing three charges in the 2022 death of her police officer boyfriend, John O'Keefe, including second-degree murder. Her first trial ended with a hung jury. Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' Nancy Chen reports on the qualifications for the discount and what the cost reduction will be. Artificial intelligence is being used to create realistic video and audio to impersonate people, in some cases looking for love or deceiving companies looking to hire. In a 2024 study, half of the businesses surveyed said they'd experienced AI deepfake fraud. CBS News MoneyWatch correspondent Kelly O'Grady reports. In this week's "Beg-Knows America," CBS News contributor David Begnaud revisits the life-changing world of high school speech and debate, an activity that shaped his own path. He meets the inspiring young voices featured in the new documentary "SPEAK," tackling grief, identity, and advocacy with extraordinary courage. Consumer Reports' deputy editor Brian Vines joins "CBS Mornings" to share the latest sunscreen testing results, including top-rated picks and expert tips to keep you and your family safe in the sun this summer. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should drive all stakeholders to come together to figure out how to safely treat patients with this new modality. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the opportunity FDA, companies and patient advocates have to share data and identify a safe path forward for the gene therapy field, both in DMD and beyond.The analysts also review promising early data for amylin agonists to treat obesity from Metsera and Eli Lilly, and discuss the vision for FDA's future laid out by Commissioner Marty Makary and CBER director Vinay Prasad. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656214#biotech #biopharma #pharma #lifescience #obesity #FDA #DMD00:01 - Sponsor Message: ICON Biotech01:19 - Gene Therapy Safety11:55 - Amylin in Obesity18:17 - FDA's FutureTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode, Dr. Ashwin Parihar speaks with Dr. Petrice Cogswell about the radiologist's critical role in diagnosing Alzheimer's disease and how imaging advances are reshaping early detection. They also explore how innovation at scale, platform thinking, and operational alignment drive progress across complex healthcare systems. This episode is sponsored by Eli Lilly and Company.

EP. 215: I sat down with Brad Hart, owner of Forest Park Pharmacy in Fort Worth, to expose the shocking truth behind pharmacy benefit managers (PBMs) and how they're driving up drug prices. What I learned about vertical integration in the healthcare system, where insurers own the PBMs and the pharmacies, honestly left me furious. Brad breaks it all down, from Medicare waste to the skyrocketing cost of specialty drugs, and we talk about real solutions like compounding pharmacies and direct-to-consumer options. This is a must-listen if you've ever wondered why your medications cost so much—and who's really profiting. Topics Discussed:  What are pharmacy benefit managers (PBMs) and how do they increase drug prices? How are health insurance companies profiting from vertical integration in the pharmacy system? Why are independent and rural pharmacies struggling to stay open? What impact do PBMs have on Medicare spending and prescription drug costs? How can consumers save money on medications without relying on insurance? Sponsored By: Qualia | Go to qualialife.com/DRTYNA for up to 50% off your purchase and use code DRTYNA for an additional 15% Maui Nui Venison | Head to mauinuivenison.com/DRTYNA to secure your access now.  LMNT | Get your free Sample Pack with any LMNT purchase at drinkLMNT.com/drtyna BIOptimizers | Go to bioptimizers.com/tyna and use promo code TYNA10 to order Masszymes now and get 10% off any order Sundays | Get 40% off your first order of Sundays. Go to sundaysfordogs.com/DRTYNA and use code DRTYNA at checkout. Relax Tonic | Go to https://store.drtyna.com/products/relaxtonic and use code and use DRTYNASHOW to save 10% On This Episode We Cover:  00:00:00 - Introduction  00:04:34 - History of PBMs 00:09:02 - Insurance & Pharmacy Ties 00:12:17 - UnitedHealthcare's Role 00:15:59 - Pharmacy Kickbacks 00:18:01 - Emergency Med Access 00:23:11 - Rural Pharmacy Crisis 00:26:20 - How Insurance Works 00:30:05 - Compounding Pharmacies Explained 00:35:19 - How Pharmacies Save Money 00:37:14 - Arkansas PBM Bill 00:39:12 - Trump's Drug Pricing Executive Order 00:42:37 - Direct-to-Consumer Drugs 00:43:40 - Wegovy, Eli Lilly, & Changing Costs 00:46:27 - Medicare Waste 00:48:25 - Medicare Price Negotiation 00:49:58 - Specialty Drug Cost 00:54:18 - Brad's Pharmacy Model Further Listening:  The Fight For Affordable GLP1s & The Truth About Big Pharma | Dave Knapp  Check Out Brad:  https://www.forestparkpharmacy.com/ Instagram TikTok YouTube Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

In this insightful Market Mondays clip, Rashad Bilal, Ian Dunlap, and Troy Millings break down two of the week's biggest financial headlines that could shake up the markets: President Trump's executive order to lower prescription drug prices and Amazon's strategic acquisition of AMD shares. First, the hosts dive deep into the possible long-term impacts of Trump's new executive order aiming to slash prescription drug costs across the board. They discuss the potential winners—everyday consumers in need of lower medication costs—and the possible losers, notably major pharmaceutical companies that may see profit margins squeezed. The conversation covers how this move could spur much-needed innovation within the healthcare sector, but also draws attention to challenges such as lobbying pressure and lengthy litigation. What does this mean for healthcare stocks like Pfizer, Eli Lilly, Novo Nordisk, Johnson & Johnson, CVS, Amgen, and more? The hosts lay out possible outcomes and the bigger economic picture, including references to Mark Cuban's earlier ideas about drug pricing and fair access.Next up, the crew unpacks the real story behind Amazon's much-discussed “purchase” of $84 million in AMD shares. Is this a direct investment or the result of AMD's acquisition of ZT Group International—where Amazon already had stakes? They clarify the technical details and examine how this plays into Amazon's push for self-reliance in AI infrastructure and chip development, following in the footsteps of giants like Apple making their own chips. The discussion also touches on how this integration of hardware and internal resources could position Amazon for even more dominance in the AI race and tech industry at large.Throughout the clip, Rashad, Ian, and Troy provide honest takes on market strategies, investment insights, and the political chess game playing out in real time. From healthcare innovation to tech self-sufficiency, this conversation is a must-watch for investors, entrepreneurs, and anyone wanting to stay ahead of the curve on Wall Street.Don't forget to like, comment, and subscribe for more in-depth market analysis and actionable insights!#MarketMoves #PrescriptionDrugs #HealthcareStocks #TrumpNews #Amazon #AMD #TechStocks #AI #Investing #StockMarket #Finance #BusinessNews #MarkCuban #Pharma #EliLilly #Pfizer #JohnsonAndJohnson #Pharmaceuticals #Innovation #BusinessAnalysis #AmazonPrime #WallStreet #FinancialNewsSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Tenemos en esta ocasión un capítulo especial. Nos adentramos en la historia de la diabetes, una enfermedad que pasó de ser un misterio en la antigüedad a convertirse en un reto global en el siglo XXI. Comprenderla es vital para todos, no solo por su impacto en millones de personas, sino porque revela cómo nuestros hábitos, la alimentación y situaciones sociales influyen directamente en nuestra salud y la de las personas que nos rodean. Conocer la diabetes es entender cómo vivimos y qué podemos cambiar para cuidarnos mejor. Notas del episodio: Este episodio fue patrocinado por Eli Lilly, A Medicine Company El origen de la palabra diabetes Historia de la diabetes El descubrimiento de la insulina Herramientas para conocer tu riesgo de Diabetes Datos de la ONU sobre las diabetes Y aquí les dejamos la página de la Asociación Colombiana de Diabetes  ¡Síguenos en nuestras redes sociales! Facebook: / dianauribe.fm Instagram: https://www.instagram.com/dianauribe.fm/ T witter: https://twitter.com/dianauribe.fm?lang=es Pagina web: https://www.dianauribe.fm TikTok: https://www.tiktok.com/@dianauribe.fm?is_from_webapp=1&sender_device=pc LinkedIn: https://www.linkedin.com/in/diana-uribe-/?originalSubdomain=co